Skip to main content

How Novartis is changing the way medicines are manufactured with AWS

Amazon Web Services and Novartis announce strategic collaboration to accelerate digital transformation

AWS has announced a strategic collaboration with Novartis to accelerate the digital transformation of its business operations. 

Novartis, a leading pharmaceutical company, is leveraging AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will change the way medicines are manufactured and delivered.

The multi-year strategic collaboration with Novartis will reimagine its pharmaceutical manufacturing, supply chain, and delivery operations using AWS’s portfolio of cloud services. This enterprise-wide data and analytics platform is expected to form the foundation for custom solutions powered by AWS AI and ML services to help drive agility, innovation, and cost efficiencies across Novartis’ global business processes and systems.

Core to the collaboration is the creation of Novartis ‘Insight Centres’ that provide real-time visibility across its network of manufacturing operations and distribution centres. Building on the success of its trial operations centre SENSE, these ‘Insight Centres’ can enable manufacturing and planning teams to better forecast and track production lines, detect potential bottlenecks and then make adjustment recommendations to improve accuracy. 

Using AWS, Novartis can collect inventory, quality, and production data across its network and apply AWS Internet of Things (IoT), analytics, and machine learning (ML) services to gain greater visibility and help drive efficiencies. By centralising this data, Novartis data scientists can also experiment with new optimisation models to help ramp up the production of innovative, personalised treatments that are more complex to make.

SEE ALSO:

Volkswagen partners with Amazon Web Services to transform automotive manufacturing

Salesforce launches Manufacturing Cloud platform

Pfizer and Novartis lead $2bn spending on gene therapy production

Read the latest issue of Manufacturing Global here

In addition, Novartis plans to use AWS IoT services to augment and improve visual inspections of its manufacturing sites by generating images that can be analysed using computer vision algorithms to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders. With this real-time data, Novartis associates can be better equipped to make data-based decisions that help ensure medicines are efficiently produced and distributed to nearly 1 billion patients in 155 countries around the world.

“I’m really proud of how the teams are working together on the ground to bring Amazon-like user experiences to our associates. There is a lot we can learn from the AWS team, and while manufacturing is a great starting place, we’re keen to also explore where else we can apply this technology,” said Bertrand Bodson, Chief Digital Officer at Novartis. 

“Using data science and digital technologies to reimagine the way we manufacture medicines is not only at the heart of our transformation, but also core to our ambition to bring innovative medicines to patients faster.”

“We are excited about this collaboration, bringing together AWS’s unmatched portfolio of services with deep Novartis expertise in the way they manufacture pharmaceuticals and the way they approach supply chain processes,” said Mike Clayville, Vice President, Worldwide Commercial Sales at AWS. 

“AWS’s security, scalability, and highly reliable infrastructure can help Novartis advance its technical operations with greater agility and customer-orientation, and potentially reducing the time it takes to bring innovative medicines to patients.”